Repeatability of Quantitative 18F-NaF PET: A Multicenter Study

Ronald Boellaard; Roberto Delgado-Bolton; Wim J.G. Oyen; Francesco Giammarile; Klaus Tatsch; Wolfgang Eschner; Fred J. Verzijlbergen; Sally F. Barrington; Lucy C. Pike; Wolfgang A. Weber; Sigrid Stroobants; Dominique Delbeke; Kevin J. Donohoe; Scott Holbrook; Michael M. Graham; Giorgio Testanera; Otto S. Hoekstra; Josee Zijlstra; Eric Visser; Corneline J. Hoekstra; Jan Pruim; Antoon Willemsen; Bertjan Arends; J??rg Kotzerke; Andreas Bockisch; Thomas Beyer; Arturo Chiti; Bernd J. Krause; Ana E. Brito; Allan Santos; André Deeke Sasse; Cesar Cabello; Paulo Oliveira; Camila Mosci; Tiago Souza; Barbara Amorim; Mariana Lima; Celso D. Ramos; Elba Etchebehere; Stephanie A Harmon; Timothy Perk; Chieh Christie Lin; Jens Eickhoff; Peter L. Choyke; William L. Dahut; B Andrea; John L. Humm; Steven M Larson; Michael J. Morris; Glenn Liu; Robert Jeraj; T. Bradshaw; Timothy Perk; Stephanie A Harmon; Jens Eickhoff; N. Jallow; Peter L. Choyke; William L. Dahut; Steven M Larson; John L. Humm; S. Perlman; A. B. Apolo; Michael J. Morris; Glenn Liu; Robert Jeraj; Emmanuel Itti; Corinne Haioun; Yolande Petegnief; Alain Luciani; Jehan Dupuis; Gaetano Paone; Jean-Noël Talbot; Alain Rahmouni; Michel Meignan; Brett Marinelli; Carina Espinet-Col; Gary A Ulaner; Heather L McArthur; Mithat Gonen; Maxine Jochelson; Wolfgang A. Weber; Iain Murray; Sarah J. Chittenden; Ana M. Denis-Bacelar; Cecilia Hindorf; Christopher C. Parker; Sue Chua; Glenn D. Flux

doi:https://doi.org/10.2967/jnumed.116.177295

Repeatability of Quantitative 18F-NaF PET: A Multicenter Study

Ronald Boellaard, Roberto Delgado-Bolton, Wim J.G. Oyen, Francesco Giammarile, Klaus Tatsch, Wolfgang Eschner, Fred J. Verzijlbergen, Sally F. Barrington, Lucy C. Pike, Wolfgang A. Weber, Sigrid Stroobants, Dominique Delbeke, Kevin J. Donohoe, Scott Holbrook, Michael M. Graham, Giorgio Testanera, Otto S. Hoekstra, Josee Zijlstra, Eric Visser, Corneline J. HoekstraJan Pruim, Antoon Willemsen, Bertjan Arends, J??rg Kotzerke, Andreas Bockisch, Thomas Beyer, Arturo Chiti, Bernd J. Krause, Ana E. Brito, Allan Santos, André Deeke Sasse, Cesar Cabello, Paulo Oliveira, Camila Mosci, Tiago Souza, Barbara Amorim, Mariana Lima, Celso D. Ramos, Elba Etchebehere, Stephanie A Harmon, Timothy Perk, Chieh Christie Lin, Jens Eickhoff, Peter L. Choyke, William L. Dahut, B Andrea, John L. Humm, Steven M Larson, Michael J. Morris, Glenn Liu, Robert Jeraj, T. Bradshaw, Timothy Perk, Stephanie A Harmon, Jens Eickhoff, N. Jallow, Peter L. Choyke, William L. Dahut, Steven M Larson, John L. Humm, S. Perlman, A. B. Apolo, Michael J. Morris, Glenn Liu, Robert Jeraj, Emmanuel Itti, Corinne Haioun, Yolande Petegnief, Alain Luciani, Jehan Dupuis, Gaetano Paone, Jean-Noël Talbot, Alain Rahmouni, Michel Meignan, Brett Marinelli, Carina Espinet-Col, Gary A Ulaner, Heather L McArthur, Mithat Gonen, Maxine Jochelson, Wolfgang A. Weber, Iain Murray, Sarah J. Chittenden, Ana M. Denis-Bacelar, Cecilia Hindorf, Christopher C. Parker, Sue Chua, Glenn D. Flux

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic › peer-review

55 Citations (Scopus)

Abstract

PURPOSE In bone-metastatic breast cancer patients, there are no current imaging biomarkers to identify which patients have worst prognosis. The purpose of our study was to investigate if skeletal tumor burden determined by 18F-Fluoride PET/CT correlates with clinical outcomes and may help define prognosis throughout the course of the disease. RESULTS Bone metastases were present in 49 patients. On multivariable analysis, skeletal tumor burden was significantly and independently associated with overall survival (p <0.0001) and progression free-survival (p <0.0001). The simple presence of bone metastases was associated with time to bone event (p = 0.0448). MATERIALS AND METHODS We quantified the skeletal tumor burden on 18F-Fluoride PET/CT images of 107 female breast cancer patients (40 for primary staging and the remainder for restaging after therapy). Clinical parameters, primary tumor characteristics and skeletal tumor burden were correlated to overall survival, progression free-survival and time to bone event. The median follow-up time was 19.5 months. CONCLUSIONS 18F-Fluoride PET/CT skeletal tumor burden is a strong independent prognostic imaging biomarker in breast cancer patients.

Original language	English
Title of host publication	European Journal of Nuclear Medicine and Molecular Imaging
Publisher	European Journal of Nuclear Medicine and Molecular Imaging
Pages	328-354
Number of pages	27
ISBN (Print)	1535-5667 (Electronic)\r0161-5505 (Linking)
DOIs	https://doi.org/10.2967/jnumed.116.177295
Publication status	Published - 2017

Publication series

Name	European Journal of Nuclear Medicine and Molecular Imaging
Volume	57

Keywords

-Fluoride
10
116
177295
1872
1879
18F
223Ra
2967
57
Absorbed dose
Alpha emitter
FDG
FDG PET/CT
Imaging procedure
NaF PET/CT
Oncology
PET/CT
Quantification
Radium
Treatment planning
Triple-negative metastatic breast cancer
Tumour
bone metastases
breast cancer
breast cancer prognosis
cancer
doi
early pet
fluoride-PET/CT
j nucl med 2016
jnumed
lymphoma
metabolic tumor volume
metastatic prostate
multicenter clinical trial
pet
repeatability
skeletal tumor burden
sodium fluoride
standardized uptake value

Access to Document

https://doi.org/10.2967/jnumed.116.177295

Cite this

Boellaard, R., Delgado-Bolton, R., Oyen, W. J. G., Giammarile, F., Tatsch, K., Eschner, W., Verzijlbergen, F. J., Barrington, S. F., Pike, L. C., Weber, W. A., Stroobants, S., Delbeke, D., Donohoe, K. J., Holbrook, S., Graham, M. M., Testanera, G., Hoekstra, O. S., Zijlstra, J., Visser, E., ... Flux, G. D. (2017). Repeatability of Quantitative 18F-NaF PET: A Multicenter Study. In European Journal of Nuclear Medicine and Molecular Imaging (pp. 328-354). (European Journal of Nuclear Medicine and Molecular Imaging; Vol. 57). European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.2967/jnumed.116.177295

@inbook{5daa58167f6f4141b6779d0a19ab8b34,

title = "Repeatability of Quantitative 18F-NaF PET: A Multicenter Study",

abstract = "PURPOSE In bone-metastatic breast cancer patients, there are no current imaging biomarkers to identify which patients have worst prognosis. The purpose of our study was to investigate if skeletal tumor burden determined by 18F-Fluoride PET/CT correlates with clinical outcomes and may help define prognosis throughout the course of the disease. RESULTS Bone metastases were present in 49 patients. On multivariable analysis, skeletal tumor burden was significantly and independently associated with overall survival (p <0.0001) and progression free-survival (p <0.0001). The simple presence of bone metastases was associated with time to bone event (p = 0.0448). MATERIALS AND METHODS We quantified the skeletal tumor burden on 18F-Fluoride PET/CT images of 107 female breast cancer patients (40 for primary staging and the remainder for restaging after therapy). Clinical parameters, primary tumor characteristics and skeletal tumor burden were correlated to overall survival, progression free-survival and time to bone event. The median follow-up time was 19.5 months. CONCLUSIONS 18F-Fluoride PET/CT skeletal tumor burden is a strong independent prognostic imaging biomarker in breast cancer patients.",

keywords = "-Fluoride, 10, 116, 177295, 1872, 1879, 18F, 223Ra, 2967, 57, Absorbed dose, Alpha emitter, FDG, FDG PET/CT, Imaging procedure, NaF PET/CT, Oncology, PET/CT, Quantification, Radium, Treatment planning, Triple-negative metastatic breast cancer, Tumour, bone metastases, breast cancer, breast cancer prognosis, cancer, doi, early pet, fluoride-PET/CT, j nucl med 2016, jnumed, lymphoma, metabolic tumor volume, metastatic prostate, multicenter clinical trial, pet, repeatability, skeletal tumor burden, sodium fluoride, standardized uptake value",

author = "Ronald Boellaard and Roberto Delgado-Bolton and Oyen, {Wim J.G.} and Francesco Giammarile and Klaus Tatsch and Wolfgang Eschner and Verzijlbergen, {Fred J.} and Barrington, {Sally F.} and Pike, {Lucy C.} and Weber, {Wolfgang A.} and Sigrid Stroobants and Dominique Delbeke and Donohoe, {Kevin J.} and Scott Holbrook and Graham, {Michael M.} and Giorgio Testanera and Hoekstra, {Otto S.} and Josee Zijlstra and Eric Visser and Hoekstra, {Corneline J.} and Jan Pruim and Antoon Willemsen and Bertjan Arends and J??rg Kotzerke and Andreas Bockisch and Thomas Beyer and Arturo Chiti and Krause, {Bernd J.} and Brito, {Ana E.} and Allan Santos and Sasse, {Andr{\'e} Deeke} and Cesar Cabello and Paulo Oliveira and Camila Mosci and Tiago Souza and Barbara Amorim and Mariana Lima and Ramos, {Celso D.} and Elba Etchebehere and Harmon, {Stephanie A} and Timothy Perk and Lin, {Chieh Christie} and Jens Eickhoff and Choyke, {Peter L.} and Dahut, {William L.} and B Andrea and Humm, {John L.} and Larson, {Steven M} and Morris, {Michael J.} and Glenn Liu and Robert Jeraj and T. Bradshaw and Timothy Perk and Harmon, {Stephanie A} and Jens Eickhoff and N. Jallow and Choyke, {Peter L.} and Dahut, {William L.} and Larson, {Steven M} and Humm, {John L.} and S. Perlman and Apolo, {A. B.} and Morris, {Michael J.} and Glenn Liu and Robert Jeraj and Emmanuel Itti and Corinne Haioun and Yolande Petegnief and Alain Luciani and Jehan Dupuis and Gaetano Paone and Jean-No{\"e}l Talbot and Alain Rahmouni and Michel Meignan and Brett Marinelli and Carina Espinet-Col and Ulaner, {Gary A} and McArthur, {Heather L} and Mithat Gonen and Maxine Jochelson and Weber, {Wolfgang A.} and Iain Murray and Chittenden, {Sarah J.} and Denis-Bacelar, {Ana M.} and Cecilia Hindorf and Parker, {Christopher C.} and Sue Chua and Flux, {Glenn D.}",

year = "2017",

doi = "https://doi.org/10.2967/jnumed.116.177295",

language = "English",

isbn = "1535-5667 (Electronic)\r0161-5505 (Linking)",

series = "European Journal of Nuclear Medicine and Molecular Imaging",

publisher = "European Journal of Nuclear Medicine and Molecular Imaging",

pages = "328--354",

booktitle = "European Journal of Nuclear Medicine and Molecular Imaging",

}

Boellaard, R, Delgado-Bolton, R, Oyen, WJG, Giammarile, F, Tatsch, K, Eschner, W, Verzijlbergen, FJ, Barrington, SF, Pike, LC, Weber, WA, Stroobants, S, Delbeke, D, Donohoe, KJ, Holbrook, S, Graham, MM, Testanera, G, Hoekstra, OS , Zijlstra, J, Visser, E, Hoekstra, CJ, Pruim, J, Willemsen, A, Arends, B, Kotzerke, J, Bockisch, A, Beyer, T, Chiti, A, Krause, BJ, Brito, AE, Santos, A, Sasse, AD, Cabello, C, Oliveira, P, Mosci, C, Souza, T, Amorim, B, Lima, M, Ramos, CD, Etchebehere, E, Harmon, SA, Perk, T, Lin, CC, Eickhoff, J, Choyke, PL, Dahut, WL, Andrea, B, Humm, JL, Larson, SM, Morris, MJ, Liu, G, Jeraj, R, Bradshaw, T, Perk, T, Harmon, SA, Eickhoff, J, Jallow, N, Choyke, PL, Dahut, WL, Larson, SM, Humm, JL, Perlman, S, Apolo, AB, Morris, MJ, Liu, G, Jeraj, R, Itti, E, Haioun, C, Petegnief, Y, Luciani, A, Dupuis, J, Paone, G, Talbot, J-N, Rahmouni, A, Meignan, M, Marinelli, B, Espinet-Col, C, Ulaner, GA, McArthur, HL, Gonen, M, Jochelson, M, Weber, WA, Murray, I, Chittenden, SJ, Denis-Bacelar, AM, Hindorf, C, Parker, CC, Chua, S & Flux, GD 2017, Repeatability of Quantitative 18F-NaF PET: A Multicenter Study. in European Journal of Nuclear Medicine and Molecular Imaging. European Journal of Nuclear Medicine and Molecular Imaging, vol. 57, European Journal of Nuclear Medicine and Molecular Imaging, pp. 328-354. https://doi.org/10.2967/jnumed.116.177295

Repeatability of Quantitative 18F-NaF PET: A Multicenter Study. / Boellaard, Ronald; Delgado-Bolton, Roberto; Oyen, Wim J.G. et al.
European Journal of Nuclear Medicine and Molecular Imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017. p. 328-354 (European Journal of Nuclear Medicine and Molecular Imaging; Vol. 57).

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic › peer-review

TY - CHAP

T1 - Repeatability of Quantitative 18F-NaF PET: A Multicenter Study

AU - Boellaard, Ronald

AU - Delgado-Bolton, Roberto

AU - Oyen, Wim J.G.

AU - Giammarile, Francesco

AU - Tatsch, Klaus

AU - Eschner, Wolfgang

AU - Verzijlbergen, Fred J.

AU - Barrington, Sally F.

AU - Pike, Lucy C.

AU - Weber, Wolfgang A.

AU - Stroobants, Sigrid

AU - Delbeke, Dominique

AU - Donohoe, Kevin J.

AU - Holbrook, Scott

AU - Graham, Michael M.

AU - Testanera, Giorgio

AU - Hoekstra, Otto S.

AU - Zijlstra, Josee

AU - Visser, Eric

AU - Hoekstra, Corneline J.

AU - Pruim, Jan

AU - Willemsen, Antoon

AU - Arends, Bertjan

AU - Kotzerke, J??rg

AU - Bockisch, Andreas

AU - Beyer, Thomas

AU - Chiti, Arturo

AU - Krause, Bernd J.

AU - Brito, Ana E.

AU - Santos, Allan

AU - Sasse, André Deeke

AU - Cabello, Cesar

AU - Oliveira, Paulo

AU - Mosci, Camila

AU - Souza, Tiago

AU - Amorim, Barbara

AU - Lima, Mariana

AU - Ramos, Celso D.

AU - Etchebehere, Elba

AU - Harmon, Stephanie A

AU - Perk, Timothy

AU - Lin, Chieh Christie

AU - Eickhoff, Jens

AU - Choyke, Peter L.

AU - Dahut, William L.

AU - Andrea, B

AU - Humm, John L.

AU - Larson, Steven M

AU - Morris, Michael J.

AU - Liu, Glenn

AU - Jeraj, Robert

AU - Bradshaw, T.

AU - Perk, Timothy

AU - Harmon, Stephanie A

AU - Eickhoff, Jens

AU - Jallow, N.

AU - Choyke, Peter L.

AU - Dahut, William L.

AU - Larson, Steven M

AU - Humm, John L.

AU - Perlman, S.

AU - Apolo, A. B.

AU - Morris, Michael J.

AU - Liu, Glenn

AU - Jeraj, Robert

AU - Itti, Emmanuel

AU - Haioun, Corinne

AU - Petegnief, Yolande

AU - Luciani, Alain

AU - Dupuis, Jehan

AU - Paone, Gaetano

AU - Talbot, Jean-Noël

AU - Rahmouni, Alain

AU - Meignan, Michel

AU - Marinelli, Brett

AU - Espinet-Col, Carina

AU - Ulaner, Gary A

AU - McArthur, Heather L

AU - Gonen, Mithat

AU - Jochelson, Maxine

AU - Weber, Wolfgang A.

AU - Murray, Iain

AU - Chittenden, Sarah J.

AU - Denis-Bacelar, Ana M.

AU - Hindorf, Cecilia

AU - Parker, Christopher C.

AU - Chua, Sue

AU - Flux, Glenn D.

PY - 2017

Y1 - 2017

N2 - PURPOSE In bone-metastatic breast cancer patients, there are no current imaging biomarkers to identify which patients have worst prognosis. The purpose of our study was to investigate if skeletal tumor burden determined by 18F-Fluoride PET/CT correlates with clinical outcomes and may help define prognosis throughout the course of the disease. RESULTS Bone metastases were present in 49 patients. On multivariable analysis, skeletal tumor burden was significantly and independently associated with overall survival (p <0.0001) and progression free-survival (p <0.0001). The simple presence of bone metastases was associated with time to bone event (p = 0.0448). MATERIALS AND METHODS We quantified the skeletal tumor burden on 18F-Fluoride PET/CT images of 107 female breast cancer patients (40 for primary staging and the remainder for restaging after therapy). Clinical parameters, primary tumor characteristics and skeletal tumor burden were correlated to overall survival, progression free-survival and time to bone event. The median follow-up time was 19.5 months. CONCLUSIONS 18F-Fluoride PET/CT skeletal tumor burden is a strong independent prognostic imaging biomarker in breast cancer patients.

AB - PURPOSE In bone-metastatic breast cancer patients, there are no current imaging biomarkers to identify which patients have worst prognosis. The purpose of our study was to investigate if skeletal tumor burden determined by 18F-Fluoride PET/CT correlates with clinical outcomes and may help define prognosis throughout the course of the disease. RESULTS Bone metastases were present in 49 patients. On multivariable analysis, skeletal tumor burden was significantly and independently associated with overall survival (p <0.0001) and progression free-survival (p <0.0001). The simple presence of bone metastases was associated with time to bone event (p = 0.0448). MATERIALS AND METHODS We quantified the skeletal tumor burden on 18F-Fluoride PET/CT images of 107 female breast cancer patients (40 for primary staging and the remainder for restaging after therapy). Clinical parameters, primary tumor characteristics and skeletal tumor burden were correlated to overall survival, progression free-survival and time to bone event. The median follow-up time was 19.5 months. CONCLUSIONS 18F-Fluoride PET/CT skeletal tumor burden is a strong independent prognostic imaging biomarker in breast cancer patients.

KW - -Fluoride

KW - 10

KW - 116

KW - 177295

KW - 1872

KW - 1879

KW - 18F

KW - 223Ra

KW - 2967

KW - 57

KW - Absorbed dose

KW - Alpha emitter

KW - FDG

KW - FDG PET/CT

KW - Imaging procedure

KW - NaF PET/CT

KW - Oncology

KW - PET/CT

KW - Quantification

KW - Radium

KW - Treatment planning

KW - Triple-negative metastatic breast cancer

KW - Tumour

KW - bone metastases

KW - breast cancer

KW - breast cancer prognosis

KW - cancer

KW - doi

KW - early pet

KW - fluoride-PET/CT

KW - j nucl med 2016

KW - jnumed

KW - lymphoma

KW - metabolic tumor volume

KW - metastatic prostate

KW - multicenter clinical trial

KW - pet

KW - repeatability

KW - skeletal tumor burden

KW - sodium fluoride

KW - standardized uptake value

U2 - https://doi.org/10.2967/jnumed.116.177295

DO - https://doi.org/10.2967/jnumed.116.177295

M3 - Chapter

C2 - 27445292

SN - 1535-5667 (Electronic)\r0161-5505 (Linking)

T3 - European Journal of Nuclear Medicine and Molecular Imaging

SP - 328

EP - 354

BT - European Journal of Nuclear Medicine and Molecular Imaging

PB - European Journal of Nuclear Medicine and Molecular Imaging

ER -

Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W et al. Repeatability of Quantitative 18F-NaF PET: A Multicenter Study. In European Journal of Nuclear Medicine and Molecular Imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2017. p. 328-354. (European Journal of Nuclear Medicine and Molecular Imaging). doi: https://doi.org/10.2967/jnumed.116.177295